Halozyme Therapeutics (HALO) Nyanmɛn Kpɛn
Halozyme Therapeutics
Nɛnɛn kpanlan$113.91Kpɛn 25 Sep 2026 19:59 UTC
Chɛ̀ndʒ-1.14%
AI bɛ́nɛ́nɛ́: HALO
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
Halozyme Therapeutics, Inc. is a biopharmaceutical company that produces treatments for diabetes, cancer, and skin diseases. The company focuses on developing new drug delivery methods. Its technology platform is based on recombinant human hyaluronidase and additional enzymes.
